argenx SE is a European public company and a clinical-stage biopharmaceutical company incorporated under the laws of the Netherlands with its statutory seat in Rotterdam, the Netherlands, which is listed in Belgium and the United States of America.
What is difficult is getting up and taking action.
argenx announced on January 20 that Japan’s Ministry of Health, Labour and Welfare has approved VYVGARTTM intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies. VYVGART is the first-and-only neonatal Fc receptor blocker approved in Japan.
This neonatal Fc receptor blocker is indicated for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive. Generalized myasthenia gravis is characterized by debilitating muscle weakness and fatigue. Despite taking an average of 2.3 current treatments, 61% of patients have poor well-being according to WHO-5 Index
Think about that.
People living with gMG around the world continue to experience severe disease burden despite treatment with commonly-used therapies. We are extremely proud to deliver the first-and-only approved FcRn blocker in Japan to a broad population of gMG patients, regardless of antibody status. Our commercial teams are ready and motivated to be serving as many people as possible who are living with this debilitating disease and we look forward to collaborating with the Japanese government to enable patient access. With today’s approval of VYVGART in Japan, the recent U.S. FDA approval, and ongoing review of our application in Europe, we continue to advance rapidly toward achieving our goal of delivering this innovative, targeted treatment option globally.
What else do you want to get done?
As of the first half of 2021, the company had cash and cash equivalents and current financial assets of €2.730.997 million.